HAWKINS INC. - 10-Q Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2006, and the nine-month period ended on the same date. Hawkins, Inc. operates three reportable segments: Industrial, Water Treatment, and Pharmaceutical. The company manufactures and distributes bulk chemicals, water treatment products, and pharmaceutical products. The filing was signed on May 7, 2007, and notes that the company is an Accelerated Filer.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2006 | Nine Months Ended Dec 31, 2006 |
|---|---|---|
| Sales | $37,039,181 | $120,700,006 |
| Gross Margin | $6,991,206 (18.9%) | $28,990,938 (24.0%) |
| Net Income | $314,273 | $6,260,368 |
| Earnings Per Share (Basic/Diluted) | $0.03 | $0.62 |
| Cash and Cash Equivalents | $8,025,132 | $8,025,132 (Ending Balance) |
| Net Cash from Operating Activities | N/A | $7,558,850 |
| Total Current Assets | $57,458,284 | $57,458,284 |
| Total Current Liabilities | $18,172,485 | $18,172,485 |
Debt and Liquidity: The company reported no long-term debt in the liabilities section, listing only "Other Long-Term Liabilities" of $125,944. Liquidity is supported by cash, cash equivalents, and investments available-for-sale totaling approximately $22.2 million in current assets.
Material Changes vs. Prior Period
- Sales Growth: Sales increased 7.8% for the quarter and 13.0% for the nine-month period compared to the prior year. The Industrial segment grew 8.9% (quarter) and 14.1% (nine months), while the Water Treatment segment grew 14.1% (quarter) and 16.0% (nine months).
- Pharmaceutical Decline: Pharmaceutical sales decreased 27.4% for the quarter and 12.0% for the nine months due to FDA restrictions on certain products.
- Profitability: Net income for the quarter dropped significantly to $314,273 from $1,827,264 in the prior year. This was driven by a 42.6% increase in Selling, General, and Administrative (SG&A) expenses, largely due to Enterprise Resource Planning (ERP) system implementation costs.
- Margins: Gross margin percentage decreased to 18.9% for the quarter (from 21.0% prior year) due to LIFO inventory valuation impacts and product mix changes. Operating income margin fell to 0.7% for the quarter from 7.3% in the prior year.
- Cash Flow: Net cash provided by operating activities increased to $7.56 million for the nine-month period from $4.33 million in the prior year, primarily due to fluctuations in inventory and accounts payable.
Guidance, Outlook, and Risks
- ERP Implementation: The company implemented a new ERP system in October 2006. This resulted in significant SG&A increases (approx. $670,000 in consulting fees for the quarter) and caused a delay in filing this report. Management expects these costs to remain consistent in the next quarter and decrease in fiscal 2008.
- FDA Restrictions: The company received a warning letter from the FDA in September 2006 regarding packaging validation and expiration dating. Shipments of certain pharmaceutical products were suspended. While some clearance has been received, sales for the fourth quarter of fiscal 2007 are expected to decrease compared to the prior year. Approximately $100,000 of inventory is currently unsellable.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of December 31, 2006, due to transitional issues with the new ERP system. Manual controls were implemented as a temporary measure.
- Outlook: Management expects capital expenditures for the remainder of the fiscal year to be comparable to previous years. The company does not anticipate a need for significant external financing due to strong cash flows and a low debt-to-capital ratio.
- Unusual Items: A litigation settlement gain of $1,015,826 was recorded in the prior year (fiscal 2006) related to the Universal Chemicals acquisition, which is not present in the current period.
Investor Verification Checklist
- ERP Impact: Verify the timeline for full ERP integration and the projected reduction in SG&A expenses in fiscal 2008.
- FDA Resolution: Monitor the status of the FDA warning letter and the timeline for resuming full sales of restricted pharmaceutical products.
- Internal Controls: Review future filings for confirmation that internal controls over financial reporting have been deemed effective following the ERP transition.
- LIFO Reserve: Assess the impact of raw material cost fluctuations (specifically caustic soda) on future gross margins given the company's LIFO inventory valuation method.
- Investment Portfolio: Review the valuation of the $14.2 million in available-for-sale investments, noting that $3.3 million is classified as non-current due to temporary impairment.